Vantage Vascular is one of just over 10 U.S. practices chosen to participate in the landmark RESORB clinical test for knee osteoarthritis pain.
Brooklyn, NY, United States, 10th Jul 2026 – Vantage Vascular, an outpatient vascular and interventional radiology practice serving patients across New York and New Jersey, has been selected as one of just over 10 leading U.S. clinical sites chosen to participate in the RESORB clinical test, a landmark national study evaluating a breakthrough, non-surgical treatment for knee osteoarthritis pain.
Being named a RESORB test site is not automatic. NEXTBIOMEDICAL, the study sponsor, specifically sought out practices with the clinical expertise, imaging capabilities, and patient-first infrastructure to effectively conduct a pivotal FDA test.
RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain) is a pivotal, FDA-approved clinical test comparing genicular artery embolization (GAE) using an investigational device called Nexsphere F to a standard corticosteroid knee injection. The test is enrolling approximately 126 patients across more than 10 U.S. sites and is registered on ClinicalTrials.gov as NCT06872567.
Genicular artery embolization is a minimally invasive, outpatient procedure in which board-certified interventional radiologists use image guidance to deliver tiny particles into blood vessels feeding the inflamed tissues of the knee.
Nexsphere F is a novel, fast-resorbable microsphere technology. Unlike permanent embolic agents, Nexsphere F microspheres dissolve naturally within 2 to 6 hours after the procedure.
Term blockage of blood flow. The device has already received FDA Breakthrough Device Designation, CMS IDE Category B approval (meaning Medicare covers the procedure during the test), and CE-MDD certification in Europe, where it has been used in thousands of procedures with a strong safety record.
Why Being a Selected test Site Matters for Patients
Clinical test site selection for an FDA pivotal study is highly competitive. Sponsors identify practices based on physician expertise, procedural volume, imaging infrastructure, and the ability to safely manage research protocols.
For patients, what this means in practice is significant: Vantage Vascular is offering access to a treatment not yet available anywhere outside of these select test sites in the United States. If you have knee osteoarthritis pain that has persisted despite medications and conservative care for at least two months, and you are not currently planning knee surgery or replacement, you may be eligible to receive this FDA-monitored, cutting-edge procedure at no cost through the test.
The test’s national Principal Investigator and Chief Medical Officer for NEXTBIOMEDICAL is Dr. Ziv J. Haskal, MD, Professor of Interventional Radiology at the University of Virginia. The clinical evidence behind Nexsphere F continues to grow: a published study in the Journal of Vascular and Interventional Radiology evaluating 155 patients treated with resorbable microspheres found a 67% average reduction in pain at 6 months, with no device-related serious adverse events.
Who May Be Eligible
The RESORB test is enrolling adults who:
• Have knee osteoarthritis pain that has not responded adequately to conservative treatments for at least 2 months
• Are not currently planning knee surgery or knee replacement
• Meet the study’s eligibility criteria as reviewed by Vantage Vascular’s clinical team
If enrolled, participants are randomly assigned to receive either GAE with Nexsphere F or a corticosteroid knee injection. Those initially assigned to the corticosteroid injection have the option to receive GAE after 180 days. The test runs approximately 12 to 18 months, and participation is always voluntary.
The test is FDA-IDE and IRB-approved (IRB approval at the protocol level: October 31, 2025). During the test, the procedure is covered under CMS IDE Category B, meaning Medicare-eligible patients may have coverage for test participation.
Schedule a Consultation at Vantage Vascular
If you or someone you know has been living with chronic knee pain, now is the time to explore whether you qualify. Vantage Vascular’s team will evaluate your history, imaging, and treatment background to determine eligibility and walk you through every step of the process with the same compassionate, patient-first care the practice is known for.
Enrollment is currently open at Vantage Vascular’s Brooklyn and New Jersey locations. Call or visit the practice online to schedule a consultation.
Brooklyn Flatlands Clinic: 2035 Ralph Ave, Suite B5, Brooklyn, NY 11234
Brooklyn Midwood Clinic: 603 Rugby Road, Suite 3, Brooklyn, NY 11230
New Jersey Fair Lawn Clinic: 15-01 Broadway, Suites 1–3, Fair Lawn, NJ 07410
NY: (718) 247-8794 | NJ: (201) 812-2929 | Monday–Friday: 8AM–6PM | vantagevascular.com
About Vantage Vascular
Vantage Vascular is an outpatient vascular and interventional radiology practice with locations in Brooklyn, New York and Fair Lawn, New Jersey. Led by Dr. Vishal K. Sinha, MD (Founder & President) and Dr. Christopher M. Harnain, MD, MBA, RPVI (Chief of Interventional Radiology & Founding Member), the practice’s Ivy League-educated, board-certified interventional radiologists deliver world-class, minimally invasive treatments for joint pain, vascular conditions, women’s health, and more — all in a comfortable outpatient setting, with no hospital stays or prolonged recovery. Vantage Vascular is dedicated to advancing patient care through innovation, clinical excellence, and a deep commitment to the communities of New York and New Jersey.
About the RESORB test
RESORB is a randomized, open-label, FDA-IDE and IRB-approved pivotal clinical test evaluating genicular artery embolization with Nexsphere F against intra-articular corticosteroid knee injection for osteoarthritic knee pain. The study is registered on ClinicalTrials.gov as NCT06872567, with an estimated enrollment of 126 participants at more than 10 leading U.S. clinical sites. Nexsphere F has received FDA Breakthrough Device Designation, CMS IDE Category B approval, and CE-MDD certification in Europe.
Important Research Notice
Nexsphere F is an investigational device not yet approved or cleared by the FDA for commercial use in the United States. It is available only through the RESORB clinical test at authorized test sites. Participation is subject to eligibility criteria, informed consent, site availability, and investigator review. Individual results may vary. Medicare coverage under CMS IDE Category B applies to eligible participants during the test period; patients should confirm coverage with Vantage Vascular and their insurer.
Media Contact
Organization: Vantage Vascular
Contact Person: Vishal K. Sinha
Website: https://vantagevascular.com/
Email: Send Email
Contact Number: +17182478794
Address:2035 Ralph Ave Ste B
City: Brooklyn
State: NY
Country:United States
Release id:46614
The post Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section